Public leery of third-party partnerships

Share this article:
A survey of public attitudes toward drug company partnerships with nonprofits has found skepticism of industry motives.

Among respondents to the Envision Solutions survey, 43% said pharmas fund groups like the American Heart Association and the National Kidney Foundation primarily to boost sales of their medicines.

The survey suggests a hardening of attitudes toward such partnerships. By contrast, only 10% of respondents to a similar question in a PRWeek/Barkley Public Relations poll last year said pharmas partner with non-profits primarily to boost profits.

Envision Solutions pointed to media coverage of “disease mongering” as a likely factor driving cynicism. The consultancy said the number of reports on that topic increased 775% from 2005 to 2006.

The online survey of 1,062 US adults was conducted by polling firm Kelton Research from April 10-13.

Share this article:

Email Newsletters

More in News

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds